Skip to main content
. 2015 Nov 7;126:347–354. doi: 10.1007/s11060-015-1975-y

Table 2.

Differences in demographic and clinical characteristics between patients with and without seizure reduction at 6, 12 and 18 months after the start of temozolomide

Seizure reduction at 6mo (n = 51) Seizure reduction at 12mo (n = 38) Seizure reduction at 18mo (n = 34)
<50 % ≥50 % p value <50 % ≥50 % p value <50 % ≥50 % p value
All patients 26 (50.9) 25 (49.1) 14 (36.8) 24 (63.2) 13 (38.2) 21 (61.8)
Mean age, y (SD) 47.5 (12.6) 46.0 (11.5) 0.65 50.7 (10.8) 45.5 (11.6) 0.18 49.2 (13.4) 45.5 (11.0) 0.39
Tumor type 0.82 0.27 0.84
 Astrocytoma 15 (57.7) 15 (60.0) 8 (57.1) 12 (50.0) 7 (53.8) 11 (52.4)
 Oligoastrocytoma 3 (11.5) 4 (16.0) 0 4 (16.7) 1 (7.7) 3 (14.3)
 Oligodendroglioma 8 (30.8) 6 (24.0) 6 (42.9) 8 (33.3) 5 (38.5) 7 (33.3)
Other focal symptoms at diagnosis (n = 49) 4 (16.0) 9 (37.5) 0.088 1 (7.7) 6 (26.1) 0.38 1 (3.5) 5 (25.0) 0.37
Extent of surgery 0.33 0.72 0.28
 Resection 17 (65.4) 13 (52.0) 9 (64.3) 14 (58.3) 10 (76.9) 11 (52.4)
 Biopsy 9 (34.6) 12 (48.0) 5 (35.7) 10 (41.7) 3 (23.1) 10 (47.6)
Radiotherapy 20 (76.9) 16 (64.0) 0.31 12 (85.7) 14 (58.3) 0.080 11 (84.6) 12 (57.1) 0.096
Seizure classification 0.12 0.94 0.64
 Partial 12 (46.2) 17 (68.0) 8 (57.1) 14 (58.3) 7 (53.8) 13 (61.9)
 Generalized or both partial and generalized 14 (53.8) 8 (32.0) 6 (42.9) 10 (41.7) 6 (46.2) 8 (38.1)
Seizure frequency 0.33 0.74 0.17
 >1/week 17 (65.4) 13 (52.0) 8 (57.1) 15 (62.5) 6 (46.2) 15 (71.4)
 <1/week 9 (34.6) 12 (48.0) 6 (42.9) 9 (37.5) 7 (53.8) 6 (28.6)
AED polytherapy 18 (69.2) 15 (60.0) 0.49 10 (71.4) 16 (66.7) 1.00 10 (76.9) 14 (66.7) 0.70
Steroid use 13 (50.0) 12 (48.0) 0.89 6 (42.9) 9 (37.5) 0.74 7 (53.8) 6 (28.6) 0.17